Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Merck & Co., Inc. MRK

Healthcare  —  Drug Manufacturers General
148.78 0.80 0.54% as of 25 Sep
Market cap
$365.4B
P/E
119×
S&P 500 Member Dividend Aristocrat Revenue Champion (5y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Merck & Co., Inc. (MRK) EV/EBITDA

As of 25 September 2026, Merck & Co., Inc. (MRK) trades at a EV/EBITDA of 30.0×. Over the past ten years it has ranged from 8.4× (May 2025) to 52.9× (March 2024); the current reading is higher than 94% of that period. That is above the Drug Manufacturers General industry median of 13.9× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 10.6× (4.11%)
FY2024 11.0× (76.01%)
FY2023 46.0× 243.62%
FY2022 13.4× 1.45%
FY2021 13.2× (44.52%)
FY2020 23.8× 13.73%
FY2019 20.9× 37.03%
FY2018 15.3× 9.85%
FY2017 13.9× (9.70%)
FY2016 15.4× 40.55%

Quarterly

Period EV/EBITDA Change
Jun 2026 26.4× 49.84%
Mar 2026 17.6× 66.44%
Dec 2025 10.6× 23.35%
Sep 2025 8.6× (6.53%)
42 more quarters

Against its own ten years

Low 8.4× High 52.9×
Ten-year median 15.1×
Current reading's percentile 94

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
PFE Pfizer Inc. compare 10.5×
AZN AstraZeneca PLC compare 13.9×
NVS Novartis AG compare 14.0×
AMGN Amgen Inc. compare 16.2×
JNJ Johnson & Johnson compare 19.2×
ABBV AbbVie Inc. compare 20.8×
MRK Merck & Co., Inc. 30.0×
GILD Gilead Sciences, Inc. compare 804×
Drug Manufacturers General industry median 13.9×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on MRK